Review of atypical antipsychotics in anxiety.

@article{Vulink2011ReviewOA,
  title={Review of atypical antipsychotics in anxiety.},
  author={Nienke C. C. Vulink and Martijn Figee and D. Denys},
  journal={European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  year={2011},
  volume={21 6},
  pages={429-49}
}
Atypical antipsychotics are increasingly used for treatment of anxiety disorders, either in mono- or combination therapy. This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety (disorders) comorbid to schizophrenia, bipolar disorder (BPD) and major depressive disorder (MDD). We included 49 open-label trials, 32 randomized, placebo-controlled trials (RCTpls) and five randomized controlled… CONTINUE READING

3 Figures & Tables

Connections & Topics

Mentioned Connections BETA
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
This is the first review reporting on the use of atypical antipsychotics in monotherapy or augmentation in patients with primary anxiety disorders or anxiety ( disorders ) comorbid to schizophrenia , bipolar disorder ( BPD ) and major depressive disorder ( MDD ) .
All Topics